Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTX Avalo Therapeutics	$4.78 +0.4%	$4.42	$3.39 ▼ $16.00	$51.77M	0.7	61,108 shs	92,801 shs
CRDF Cardiff Oncology	$3.15 -0.3%	$3.12	$2.01 ▼ $5.64	$209.57M	1.61	1.18 million shs	2.15 million shs
FULC Fulcrum Therapeutics	$7.10 -3.8%	$6.02	$2.32 ▼ $10.13	$383.26M	2.4	915,043 shs	1.21 million shs
IVA Inventiva	$3.04 -4.2%	$3.43	$1.53 ▼ $4.05	$290.42M	0.76	64,517 shs	7,534 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTX Avalo Therapeutics	0.00%	+3.02%	+21.01%	-40.32%	-61.67%
CRDF Cardiff Oncology	0.00%	+1.61%	-5.69%	+0.32%	+41.89%
FULC Fulcrum Therapeutics	0.00%	+1.57%	+3.50%	+146.53%	+14.52%
IVA Inventiva	0.00%	-7.72%	-3.03%	+4.51%	+1.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVTX Avalo Therapeutics	3.1962 of 5 stars	3.5	3.0	2.7	1.7	1.3
CRDF Cardiff Oncology	1.6543 of 5 stars	3.4	1.0	2.7	0.0	0.6
FULC Fulcrum Therapeutics	0.2706 of 5 stars	1.3	0.0	1.3	2.5	0.0
IVA Inventiva	3.2589 of 5 stars	3.4	5.0	2.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTX Avalo Therapeutics	3.00	Buy	$30.00	527.62% Upside
CRDF Cardiff Oncology	2.80	Moderate Buy	$9.88	213.49% Upside
FULC Fulcrum Therapeutics	2.50	Moderate Buy	$6.29	-11.47% Downside
IVA Inventiva	2.80	Moderate Buy	$10.40	242.56% Upside

Current Analyst Ratings Breakdown

Latest AVTX, CRDF, IVA, and FULC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	CRDF Cardiff Oncology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$3.50
6/18/2025	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/2/2025	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$15.00
5/29/2025	FULC Fulcrum Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$6.00 ➝ $9.00
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $12.00
5/15/2025	FULC Fulcrum Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$10.00
5/9/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$17.00 ➝ $18.00
4/4/2025	IVA Inventiva	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $9.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTX Avalo Therapeutics	$440K	117.65	N/A	N/A	$12.80 per share	0.37
CRDF Cardiff Oncology	$680K	308.19	N/A	N/A	$1.86 per share	1.69
FULC Fulcrum Therapeutics	$80M	4.79	N/A	N/A	$4.51 per share	1.57
IVA Inventiva	$9.95M	29.19	N/A	N/A	($1.21) per share	-2.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTX Avalo Therapeutics	-$35.13M	N/A	0.00	N/A	N/A	N/A	111.00%	58.88%	8/11/2025 (Estimated)
CRDF Cardiff Oncology	-$45.43M	-$0.92	N/A	N/A	N/A	-8,308.50%	-76.45%	-62.85%	8/14/2025 (Estimated)
FULC Fulcrum Therapeutics	-$9.73M	-$0.07	N/A	N/A	N/A	N/A	-0.20%	-0.19%	7/30/2025 (Estimated)
IVA Inventiva	-$199.34M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest AVTX, CRDF, IVA, and FULC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	AVTX Avalo Therapeutics	-$1.07	-$1.25	-$0.18	-$1.25	N/A	N/A
5/8/2025	Q1 2025	CRDF Cardiff Oncology	-$0.19	-$0.20	-$0.01	-$0.20	$0.09 million	$0.11 million
5/1/2025	Q1 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTX Avalo Therapeutics	N/A	22.61	22.61
CRDF Cardiff Oncology	N/A	6.22	6.22
FULC Fulcrum Therapeutics	N/A	28.71	28.71
IVA Inventiva	N/A	0.92	0.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTX Avalo Therapeutics	87.06%
CRDF Cardiff Oncology	16.29%
FULC Fulcrum Therapeutics	89.83%
IVA Inventiva	19.06%

Insider Ownership

Company	Insider Ownership
AVTX Avalo Therapeutics	0.25%
CRDF Cardiff Oncology	7.70%
FULC Fulcrum Therapeutics	7.00%
IVA Inventiva	32.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTX Avalo Therapeutics	40	10.83 million	10.80 million	Not Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
FULC Fulcrum Therapeutics	100	53.98 million	50.20 million	Optionable
IVA Inventiva	100	95.66 million	65.05 million	Not Optionable

AVTX, CRDF, IVA, and FULC Headlines

Recent News About These Companies

Inventiva S.A. (IVA) Latest Stock News & Headlines - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Canaccord Genuity Maintains a Buy on Inventiva (IVA) With a $20 Price Target

June 24, 2025 | msn.com

Inventiva appoints former Calliditas CEO to board of directors

June 11, 2025 | uk.investing.com

Inventiva (NASDAQ:IVA) Stock Price Up 0.8% - Here's Why

June 11, 2025 | marketbeat.com

INVENTIVA: Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors

June 11, 2025 | finanznachrichten.de

Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors

June 10, 2025 | manilatimes.netM

Inventiva S.A. (NASDAQ:IVA) Short Interest Down 12.1% in May

June 4, 2025 | marketbeat.com

Inventiva (IVA) Upgraded to Buy: What Does It Mean for the Stock?

June 3, 2025 | zacks.com

INVENTIVA: Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference

May 27, 2025 | finanznachrichten.de

Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference

May 27, 2025 | globenewswire.com

Inventiva S.A. reports Q1 results

May 23, 2025 | seekingalpha.com

INVENTIVA: Inventiva reports 2025 First Quarter Financial Information

May 23, 2025 | finanznachrichten.de

Inventiva reports 2025 First Quarter Financial Information¹

May 23, 2025 | globenewswire.com

Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025

May 23, 2025 | globenewswire.com

Description of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler Chevreux

May 22, 2025 | uk.finance.yahoo.com

INVENTIVA: Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

May 6, 2025 | finanznachrichten.de

Inventiva Secures €115.6 Million Through T2 Subscription Agreement

May 5, 2025 | tipranks.com

Inventiva secures €116 million second tranche of structured financing of up to €348 million

May 5, 2025 | msn.com

Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

May 5, 2025 | globenewswire.com

Combined General Meeting of May 22, 2025 - Availability of the preparatory documents

April 30, 2025 | globenewswire.com

Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor

April 24, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
Why SailPoint May Cruise Past Cybersecurity Rivals in 2025
By Nathan Reiff | June 18, 2025
View Why SailPoint May Cruise Past Cybersecurity Rivals in 2025

AVTX, CRDF, IVA, and FULC Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

$4.78 +0.02 (+0.42%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$9.60 +4.82 (+100.84%)

As of 04:00 AM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Cardiff Oncology NASDAQ:CRDF

$3.15 -0.01 (-0.32%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.12 -0.03 (-1.11%)

As of 04:05 AM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Fulcrum Therapeutics NASDAQ:FULC

$7.10 -0.28 (-3.79%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$7.11 +0.01 (+0.14%)

As of 04:00 AM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Inventiva NASDAQ:IVA

$3.03 -0.14 (-4.42%)

As of 06/27/2025 04:00 PM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time